P416: Metabolite measurement for thiopurine therapy in inflammatory bowel diseaseECCO '18 Vienna
2018
P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD studyECCO '18 Vienna
2018
P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitisECCO '18 Vienna
2018
P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1ECCO '18 Vienna
2018
P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCUECCO '18 Vienna
2018
P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUSTECCO '18 Vienna
2018
P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre studyECCO '18 Vienna
2018
P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulasECCO '18 Vienna
2018
P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)ECCO '18 Vienna
2018
P428: Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): Utility of and cost-saving associated with the use of a rapid assay for assessing drug levelECCO '18 Vienna
2018
P429: Robotic-assisted vs. laparoscopic proctectomy for inflammatory bowel disease: Results of the case-match comparison in single institutionECCO '18 Vienna
2018
P430: Distinct faecal bile acid profiles are associated with sustained remission following exclusive enteral nutrition (EEN) induction therapy in paediatric Crohn's diseaseECCO '18 Vienna
2018
P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodologyECCO '18 Vienna
2018
P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?ECCO '18 Vienna
2018